Milestone Scientific (MLSS)
XASE:MLSS
Want to see MLSS full AI Analyst Report?
Top Page
Milestone Scientific
(NYSE MKT:MLSS)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.35
▲(20.00% Upside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by weak financial performance (ongoing losses, negative free cash flow, and declining TTM revenue) and limited valuation visibility (P/E shown as 0.000 with no dividend yield). This is partially offset by cautiously positive earnings-call signals around cost reductions and reaffirmed growth/breakeven targets, and by neutral-to-mildly positive near-term technicals.
Positive Factors
High gross margins
Sustained ~72% gross margins indicate strong unit economics in core products, providing room to absorb SG&A as sales scale. Durable margin advantage supports potential operating leverage: as revenue grows, high gross margin can convert incremental sales into meaningful profit improvement over the 2–6 month horizon.
Negative Factors
Persistent negative cash flow
The company consistently consumes cash with negative operating and free cash flow and TTM FCF down ~37.6% year over year. This secular cash burn requires ongoing financing or rapid margin/revenue improvement; absent durable, positive cash generation, growth investments and capitalization will remain constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained ~72% gross margins indicate strong unit economics in core products, providing room to absorb SG&A as sales scale. Durable margin advantage supports potential operating leverage: as revenue grows, high gross margin can convert incremental sales into meaningful profit improvement over the 2–6 month horizon.
Read all positive factors
Milestone Scientific (MLSS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.77M
Dividend YieldN/A
Average Volume (3M)172.66K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth3.37%
EPS Growth15.78%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.06
Shares Outstanding88,075,170
10 Day Avg. Volume233,274
30 Day Avg. Volume172,658
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)7.97
Price to Sales (P/S)2.50
P/FCF Ratio-7.64
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit4.54
Enterprise Value/Ebitda-6.55
Forecast
1Y Price Target
$1.00Price Target Upside244.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$9.91M
Milestone Scientific Business Overview & Revenue Model
Company Description
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segm...
Milestone Scientific Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Positive
The call presents a cautiously positive outlook: management delivered meaningful expense reductions (>$1.3M, >30% YoY) and materially narrowed operating and net losses (both improved ~58%), while early traction in CompuFlo (medical revenue up >100% and roughly $108k in Q1), strong digital lead generation (152 leads), >50 reimbursement claims submitted, expansion of distributor and ambassador programs, and a $2.15M financing bolster the growth case. Key near-term risks remain—flat overall revenue for the quarter, a $200k shipping disruption, modest gross margin decline, CompuFlo's small absolute revenue base, and dependence on Medicare/MAC reimbursement timing and utilization to unlock nonlinear growth. Given that the positive operational improvements, financing, and early commercial traction outweigh the execution and reimbursement risks at this stage, the overall sentiment is constructive but cautious.Positive Updates
Operating Expense Reduction
Reduced operating expenses by approximately $1.3 million, representing more than a 30% year-over-year decrease, contributing to significantly narrowed losses.
Negative Updates
Flat Quarter Revenue
Total revenue held flat at approximately $2.2 million year-over-year, indicating no top-line growth in the quarter despite several growth initiatives.
Read all updates
Q1-2026 Updates
Positive
Negative
Operating Expense Reduction
Reduced operating expenses by approximately $1.3 million, representing more than a 30% year-over-year decrease, contributing to significantly narrowed losses.
Read all positive updates
Company Guidance
Management reaffirmed 2026 guidance of $9.8–$10.2 million in total revenue (double‑digit YoY growth) and a goal of reaching cash‑flow breakeven in early 2027, citing Q1 results of about $2.2M revenue, $1.56M gross profit (72.3% gross margin), operating loss of $828k (improved 58% or ~$1.2M YoY), net loss of $840k (narrowed 58% or ~$1.2M), and a >30% YoY reduction in operating expenses (~$1.3M); they expect CompuFlo to grow faster than the company overall after Q1 CompuFlo revenue of roughly $108k (more than doubled YoY), supported by 8 physician partners (6 pending), >50 reimbursement claims filed across Novitas/Palmetto/First Coast, 152 digital leads (~20–30/week), 173 ambassador applicants with 73 active ambassadors and 25 new demos, ~$200k of previously delayed Middle East bookings mostly shipped in Q2, and a post‑quarter $2.15M financing to fund sales expansion, inventory and digital marketing while driving improved operating leverage and reduced cash burn.Milestone Scientific Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.97M | 8.63M | 9.83M | 8.81M | 10.30M |
| Gross Profit | 6.33M | 6.43M | 6.79M | 4.90M | 6.31M |
| EBITDA | -5.51M | -6.72M | -7.04M | -8.76M | -7.30M |
| Net Income | -5.72M | -4.71M | -6.93M | -8.71M | -6.82M |
Balance Sheet | |||||
| Total Assets | 7.81M | 9.80M | 11.37M | 13.70M | 19.81M |
| Cash, Cash Equivalents and Short-Term Investments | 1.11M | 3.26M | 5.95M | 8.72M | 14.76M |
| Total Debt | 1.02M | 349.05K | 395.98K | 497.04K | 586.59K |
| Total Liabilities | 4.99M | 3.96M | 3.36M | 3.70M | 3.59M |
| Stockholders Equity | 2.81M | 5.83M | 8.01M | 10.23M | 16.37M |
Cash Flow | |||||
| Free Cash Flow | -2.93M | -2.93M | -5.33M | -6.04M | -4.03M |
| Operating Cash Flow | -2.92M | -2.92M | -5.33M | -6.03M | -4.02M |
| Investing Cash Flow | -15.12K | 2.97M | -2.97M | -8.53K | -15.19K |
| Financing Cash Flow | 786.34K | 233.77K | 2.56M | -8.54K | 4.57M |
Milestone Scientific Technical Analysis
Positive
0.29
Price Trends
0.28
Positive
0.29
Negative
0.41
Negative
Market Momentum
>-0.01
Positive
49.99
Neutral
24.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLSS, the sentiment is Positive. The current price of 0.29 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.28, and below the 200-day MA of 0.41, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 49.99 is Neutral, neither overbought nor oversold. The STOCH value of 24.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MLSS.
Milestone Scientific Risk Analysis
Milestone Scientific disclosed 49 risk factors in its most recent earnings report. Milestone Scientific reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Milestone Scientific Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $52.21M | -79.00 | -60.56% | ― | 64.18% | 28.90% | |
59 Neutral | $33.98M | 56.68 | 7.66% | ― | 23.25% | -3.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $28.77M | -7.04 | -173.86% | ― | 3.37% | 15.78% | |
46 Neutral | $19.16M | -1.17 | -8.13% | ― | 10.08% | 71.71% | |
46 Neutral | $21.54M | 21.30 | -258.08% | ― | 39.88% | 64.70% | |
45 Neutral | $5.98M | -1.40 | -55.33% | ― | 10.14% | 12.18% |
* Healthcare Sector Average
MLSS
Milestone Scientific
0.33
-0.70
-68.14%
RVP
Retractable Technologies
0.67
-0.08
-10.55%
POCI
Precision Optics Corporation
5.08
0.60
13.39%
NEPH
Nephros
3.68
1.53
71.16%
FEMY
Femasys
0.36
-0.68
-65.19%
NXGL
NexGel Inc
0.51
-1.88
-78.62%
Milestone Scientific Corporate Events
Business Operations and StrategyExecutive/Board Changes
Milestone Scientific Restructures Executive Equity Incentive Programs
Positive
May 6, 2026
On April 30, 2026, Milestone Scientific’s compensation committee approved a one-time stock option exchange for underwater options held by CEO Eric Hines and senior sales executive Jason Papes, resetting the exercise price to $0.31 per share,...
Business Operations and StrategyPrivate Placements and Financing
Milestone Scientific Completes Private Placement to Strengthen Finances
Positive
Apr 21, 2026
On April 20, 2026, Milestone Scientific Inc. closed a $2.15 million private placement of 7,962,963 units, each comprising one share of common stock and a warrant priced at 125% of the $0.27 unit price, with potential for an additional $2.69 millio...
Business Operations and StrategyPrivate Placements and Financing
Milestone Scientific Amends Agreement to Enhance Financing Flexibility
Positive
Apr 2, 2026
On March 31, 2026, Milestone Scientific Inc. amended a previously executed Amended and Restated Memorandum of Understanding dated January 13, 2026 with Innovest S.p.A., which holds consent and blockage rights tied to BP4 S.r.l., then the reported ...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Milestone Scientific Increases Authorized Common Shares for Flexibility
Neutral
Mar 11, 2026
At its annual meeting on December 18, 2025, Milestone Scientific Inc. stockholders approved an amendment to the company’s Restated Certificate of Incorporation to increase its authorized common shares from 100 million to 125 million. Followi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.